Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769764 · ClinicalTrials.gov registry record
A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 225
- Enrollment target
NCT05769764 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 225 participants.
The verdict
NCT05769764 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 225 participants
- Enrollment target
Study Summary
There is currently a lack of published HER3 expression prevalence data among non-small cell lung cancer (NSCLC) patients. The estimation of HER3 expression prevalence in this population using archival tissue samples and the assessment of associated patient characteristics in real world (RW) data will ultimately inform clinical strategy and increase awareness among health care providers (HCPs) and the greater medical community to improve patient care.
Interventions
- OTHER Archival tissue specimen and immunohistochemistry staining
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2023-04-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769764
The ClinicalTrials.gov registry entry for NCT05769764 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Archival tissue specimen and immunohistochemistry staining is the first listed.
NCT05769764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05769764 about?
NCT05769764 is a clinical study titled "A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer". There is currently a lack of published HER3 expression prevalence data among non-small cell lung cancer (NSCLC) patients. The estimation of HER3 expression prevalence in this population using archival tissue samples and the assessment of associated patient characteristics in real world (RW) data wil...
What is the current status of trial NCT05769764?
This trial is currently completed. The enrollment target is 225 participants. The study started on 2022-12-19. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT05769764?
The interventions under investigation include: Archival tissue specimen and immunohistochemistry staining (OTHER).
Who is sponsoring clinical trial NCT05769764?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.